Redcare Pharmacy’s Prescription Boom Faces a Mid-Year Reality Check

Redcare Pharmacy shares surged 120% from March lows, but remain 41% below peak as investors await Q2 results to gauge e-prescription growth sustainability.

The digital pharmacy operator heads into its half-year report on Wednesday with momentum that few would have predicted just four months ago. Redcare Pharmacy’s stock closed Friday at €66.05, having more than doubled from its March nadir of €30.06 — a 52-week low that now looks like a distant memory. Yet the shares remain 41% below their 52-week peak, underscoring the gap between operational progress and market valuation that investors will be scrutinizing when second-quarter numbers land.

The first quarter set a high bar. Group revenue climbed 18.4% to €849.5 million, propelled by a 55% surge in Germany’s prescription drug business — the Rx segment that has become the company’s defining growth engine. That digital prescription momentum translated into 1.1 million new active customers over the past year, bringing the total to 14.2 million. Adjusted EBITDA jumped 58% to €14.4 million, though the margin remained wafer-thin at 1.7%, a reminder that scaling the low-margin Rx business has yet to translate into meaningful profitability.

Management’s decision to raise the full-year guidance after those first-quarter results signaled confidence that the e-prescription tailwind is still building. The question hanging over Wednesday’s release is whether that pace was sustainable through the spring months or whether the second quarter brought a normalization in growth rates.

The stock’s trajectory since March tells a story of aggressive repricing. After touching the 52-week low on March 30, the shares rallied roughly 120% in a matter of weeks, pushing the price 15% above its 200-day moving average — a technical signal that the medium-term trend has shifted. But the weekly and monthly charts show a more subdued picture: the stock edged lower on both timeframes recently, and year-to-date it is essentially flat. The explosive recovery appears to have paused, settling into a consolidation phase rather than giving way to renewed selling pressure.

That consolidation comes against a backdrop of structural change in Germany’s pharmacy market. The Sanicare Group, which operates under the BS-Apotheken OHG banner, filed for insolvency in self-administration in mid-July at the Osnabrück district court, citing falling revenues and heavy investment burdens. With annual sales of roughly €80 million and 74 employees, its distress highlights the pressure on smaller players — both physical and digital — as the industry adapts to the e-prescription era.

Brick-and-mortar pharmacies are feeling the squeeze too. Düsseldorf recorded just four new pharmacy openings in the first half of the year against two closures, a net addition that does little to offset the broader trend of margin compression. From July 1, the pharmacy dispensing fee rose to €9 per pack from €8.35, but that modest relief will be partially offset by a further 30-cent increase in the mandatory rebate scheduled for 2027 — a net effect that pharmacy representatives view as a headwind. For Redcare, these dynamics tilt the competitive landscape in its favor as smaller operators struggle with rising cost structures.

The e-prescription remains the central catalyst. The 55% jump in first-quarter Rx revenue demonstrates that regulatory liberalization is translating into hard sales figures. If that trajectory holds, the upgraded full-year guidance looks achievable. But the margin story will be the key battleground for investors: the Rx segment’s contribution to profitability remains marginal, and until it moves the needle on the bottom line, the stock’s recovery will rest on growth expectations rather than earnings delivery.

Wednesday’s half-year numbers will provide the first real test of whether the first-quarter surge was a one-off or the start of a sustained trend. A confirmation of the growth trajectory, combined with further margin improvement, could reignite the rally that has stalled in recent weeks. Disappointment, however, would leave the shares trading well below their highs, with the gap to the 52-week peak likely to persist until the next catalyst emerges.